Latteno Names Chief Operating Officer to Oversee the MMJ/Healthcare Division

leafright

SANTA ANA, CA–(Marketwired – Dec 3, 2013) – Latteno Food Corp. (OTC Pink: LATF) today announced that it has appointed Trinh ‘Trina’ Ta as its new non-director, Chief Operating Officer to develop and expand its MMJ and healthcare products/services division. Ms. Ta has recently held various positions as owner/operator of several successful hair/nail, skin care […]

Terra Tech Subsidiary Edible Garden Signs Distribution Deal with 30-Acre Midwest Sustainable Hydroponic Farm

ediblegardenlogo

Belvidere, Dec. 3, 2013 (GLOBE NEWSWIRE) — Terra Tech Corp (TRTC) subsidiary Edible Garden, a hydroponic herb and produce cultivator, signed a distribution deal with Heartland Growers out of Indianapolis, Indiana. Under the terms of the deal Heartland will cultivate the full line of Edible Garden produce to be sold throughout the Midwest market. Terra Tech will manage the marketing […]

Medical Marijuana Inc.’s HempMedsPX Represents High Times Cannabis Cup Highest CBD Concentrate Award Winner

6pack_blue

SAN DIEGO, Dec. 3, 2013 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMedsPX(TM) — a corporate portfolio company of Medical Marijuana, Inc. and the exclusive master distributor and contracted marketing company for CannaVest Corp. and Medical Marijuana, Inc. — represented CBD Simple by PhytoSPHERE Systems — a CannaVest Corp. […]

GrowLife Retains Washington, D.C. Based Law Firm Crowell & Moring to Provide M&A, Regulatory Guidance

growlife

WOODLAND HILLS, Calif., Dec. 3, 2013 /PRNewswire/ — GrowLife, Inc. (PHOT), a diversified company operating in the legal cannabis industry which develops, markets and deploys products and services addressing the needs of legal cannabis growing and retail operations, including hydroponic growing equipment and retail support software, is pleased to announce that the Company has retained Washington […]

Cannabis Science (CBIS) Moves Forward with Critical Support of Landmark Federal Cannabis Legislative Initiative

CannabisScience

COLORADO SPRINGS, Colo., Dec. 2, 2013 /PRNewswire/ — (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, is a key leader in the private sector challenge to end the restrictions on cannabis drug development and research in the U.S.  “The Cannabinoid Scientific Research and Development Act,” which will be submitted […]

Endexx Lease Program Gaining Traction

m3hub

CAVE CREEK, AZ–(Marketwired – Dec 2, 2013) – Endexx Corporation (OTC Pink: EDXC) is excited to announce that the new sales team is gaining significant traction in the Washington and Colorado markets. In the early stages of rollout of the Autospense platform we are processing lease applications for 3-5 units to be delivered after the […]

GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

sativex-jpeg-resized-600

London, UK, 2 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Piper Jaffray 25th Annual Health Care […]

Nuvilex Ahead of the Curve on Cannabidiol as FDA Issues Landmark Approval

Nuvilexsq

NEW YORK, NY–(Marketwired – Nov 29, 2013) –  A new FDA approval has created a buzz inside biotechs involved with medical marijuana research. When Nuvilex, Inc. (OTCQB: NVLX) announced the formation of its new medical marijuana subsidiary, Medical Marijuana Sciences, Inc., the company’s CEO, Dr. Robert Ryan, said then that its research would focus initially on cannabidiol […]

GW Pharma rises on Swiss approval for Sativex

gw-logo

LONDON (ShareCast) – GW Pharmaceuticals (NasdaqGM:GWPH – news) has received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis (MS). A full marketing authorization has been granted by the Swissmedic authorities for Sativex in the treatment of moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medications. GW Pharma’s European […]